Journal of Virology, March 2004, p. 2790-2807, Vol. 78, No. 6
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.6.2790-2807.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor
Shawn E. Kuhmann,1 Pavel Pugach,1 Kevin J. Kunstman,2 Joann Taylor,2 Robyn L. Stanfield,3 Amy Snyder,1 Julie M. Strizki,4 Janice Riley,4 Bahige M. Baroudy,4 Ian A. Wilson,3 Bette T. Korber,5,6 Steven M. Wolinsky,2 and John P. Moore1*
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021,1
Department of Medicine, The Feinberg Medical School, Northwestern University, Chicago, Illinois 60611,2
Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037,3
Schering Plough Research Institute, Kenilworth, New Jersey 07033,4
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico 87545,5
Santa Fe Institute, Santa Fe, New Mexico 875016
Received 21 August 2003/
Accepted 18 November 2003
We have described previously the generation of an escape variant of human immunodeficiency virus type 1 (HIV-1), under the selection pressure of AD101, a small molecule inhibitor that binds the CCR5 coreceptor (A. Trkola, S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. X. L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore, Proc. Natl. Acad. Sci. USA 99:395-400, 2002). The escape mutant, CC101.19, continued to use CCR5 for entry, but it was at least 20,000-fold more resistant to AD101 than the parental virus, CC1/85. We have now cloned the env genes from the the parental and escape mutant isolates and made chimeric infectious molecular clones that fully recapitulate the phenotypes of the corresponding isolates. Sequence analysis of the evolution of the escape mutants suggested that the most relevant changes were likely to be in the V3 loop of the gp120 glycoprotein. We therefore made a series of mutant viruses and found that full AD101 resistance was conferred by four amino acid changes in V3. Each change individually caused partial resistance when they were introduced into the V3 loop of a CC1/85 clone, but their impact was dependent on the gp120 context in which they were made. We assume that these amino acid changes alter how the HIV-1 Env complex interacts with CCR5. Perhaps unexpectedly, given the complete dependence of the escape mutant on CCR5 for entry, monomeric gp120 proteins expressed from clones of the fully resistant isolate failed to bind to CCR5 on the surface of L1.2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex.
* Corresponding author. Mailing address: Department of Microbiology and Immunology, Joan and Sanford I. Weill Medical College of Cornell University, 1300 York Ave., W-805, New York, NY 10021. Phone: (212) 746-4462. Fax: (212) 746-8340. E-mail: jpm2003{at}med.cornell.edu.
Contribution la-ur-03-5893 from the Los Alamos National Laboratory.
Journal of Virology, March 2004, p. 2790-2807, Vol. 78, No. 6
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.6.2790-2807.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Yang, W., Zhao, Y., Fabrycki, J., Hou, X., Nie, X., Sanchez, A., Phadke, A., Deshpande, M., Agarwal, A., Huang, M.
(2008). Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors. Antimicrob. Agents Chemother.
52: 2043-2052
[Abstract]
[Full Text]
-
Nolan, K. M., Jordan, A. P. O., Hoxie, J. A.
(2008). Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors. J. Virol.
82: 664-673
[Abstract]
[Full Text]
-
Patel, M. B., Hoffman, N. G., Swanstrom, R.
(2008). Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins. J. Virol.
82: 903-916
[Abstract]
[Full Text]
-
Lin, G., Bertolotti-Ciarlet, A., Haggarty, B., Romano, J., Nolan, K. M., Leslie, G. J., Jordan, A. P.-O., Huang, C.-c., Kwong, P. D., Doms, R. W., Hoxie, J. A.
(2007). Replication-Competent Variants of Human Immunodeficiency Virus Type 2 Lacking the V3 Loop Exhibit Resistance to Chemokine Receptor Antagonists. J. Virol.
81: 9956-9966
[Abstract]
[Full Text]
-
Lobritz, M. A., Marozsan, A. J., Troyer, R. M., Arts, E. J.
(2007). Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity. J. Virol.
81: 8258-8269
[Abstract]
[Full Text]
-
Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T., Matsushita, S.
(2007). Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate. J. Virol.
81: 3757-3768
[Abstract]
[Full Text]
-
Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W.
(2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol.
81: 3240-3250
[Abstract]
[Full Text]
-
Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., Perros, M.
(2007). Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry. J. Virol.
81: 2359-2371
[Abstract]
[Full Text]
-
Baba, M., Miyake, H., Wang, X., Okamoto, M., Takashima, K.
(2007). Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652. Antimicrob. Agents Chemother.
51: 707-715
[Abstract]
[Full Text]
-
Whitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., Petropoulos, C. J.
(2007). Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Antimicrob. Agents Chemother.
51: 566-575
[Abstract]
[Full Text]
-
Pan, C., Kim, J., Chen, L., Wang, Q., Lee, C.
(2007). The HIV positive selection mutation database. Nucleic Acids Res
35: D371-D375
[Abstract]
[Full Text]
-
Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C.
(2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother.
50: 3289-3296
[Abstract]
[Full Text]
-
Briz, V., Poveda, E., Soriano, V.
(2006). HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother
57: 619-627
[Abstract]
[Full Text]
-
Baba, M., Takashima, K., Miyake, H., Kanzaki, N., Teshima, K., Wang, X., Shiraishi, M., Iizawa, Y.
(2005). TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob. Agents Chemother.
49: 4584-4591
[Abstract]
[Full Text]
-
Mkrtchyan, S. R., Markosyan, R. M., Eadon, M. T., Moore, J. P., Melikyan, G. B., Cohen, F. S.
(2005). Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion. J. Virol.
79: 11161-11169
[Abstract]
[Full Text]
-
Yusa, K., Maeda, Y., Fujioka, A., Monde, K., Harada, S.
(2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 Loop Library. J. Biol. Chem.
280: 30083-30090
[Abstract]
[Full Text]
-
Marozsan, A. J., Moore, D. M., Lobritz, M. A., Fraundorf, E., Abraha, A., Reeves, J. D., Arts, E. J.
(2005). Differences in the Fitness of Two Diverse Wild-Type Human Immunodeficiency Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry. J. Virol.
79: 7121-7134
[Abstract]
[Full Text]
-
Platt, E. J., Durnin, J. P., Kabat, D.
(2005). Kinetic Factors Control Efficiencies of Cell Entry, Efficacies of Entry Inhibitors, and Mechanisms of Adaptation of Human Immunodeficiency Virus. J. Virol.
79: 4347-4356
[Abstract]
[Full Text]
-
Watson, C., Jenkinson, S., Kazmierski, W., Kenakin, T.
(2005). The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor. Mol. Pharmacol.
67: 1268-1282
[Abstract]
[Full Text]
Copyright © 2004 by the American Society for Microbiology. All rights reserved.